Peng Chen
4PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jun 23, 2023
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.Yuan Gao, Yingfang Feng, Shaochuan Liu
|May 02, 2023
The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma.Ran Zuo, Fuyi Zhu, Cuicui Zhang
|Dec 19, 2022
High incidence and reversible bradycardia events following alectinib initiation.Dongqi Yuan, Fuyi Zhu, Ran Zuo
|Sep 30, 2020
Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.Ran Zuo, Cuicui Zhang, Li Lin
Pageof 1
